Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111
Debt
Debt-to-Equity Ratio0.17
Current Ratio12.22
Quick Ratio10.25
Price-To-Earnings
Trailing P/E Ratio67.09
Forward P/E Ratio66.13
P/E Growth3.04
Sales & Book Value
Annual Sales$141.24 million
Price / Sales14.32
Cash Flow$0.8779 per share
Price / Cash52.73
Book Value$13.58 per share
Price / Book3.41
Profitability
EPS (Most Recent Fiscal Year)$0.69
Net Income$28.35 million
Net Margins18.48%
Return on Equity6.06%
Return on Assets4.69%
Miscellaneous
Employees476
Outstanding Shares43,690,000
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.15 by $0.02. The biotechnology company earned $44.80 million during the quarter, compared to analysts' expectations of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The firm's quarterly revenue was up 46.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 earnings per share. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $0.69-0.73 for the period, compared to the Thomson Reuters consensus estimate of $0.70. The company issued revenue guidance of $182-188 million, compared to the consensus revenue estimate of $183.48 million.
What price target have analysts set for RGEN?
7 analysts have issued 12-month target prices for Repligen's stock. Their forecasts range from $40.00 to $50.00. On average, they anticipate Repligen's share price to reach $44.1667 in the next year. View Analyst Ratings for Repligen.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), argenx (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO) and Denali Therapeutics (DNLI).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
- Mr. Jon K. Snodgres, CFO, Sec. & Principal Accounting Officer (Age 52)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director Investor Relations
- Mr. Stephen Tingley, VP of Sales
Has Repligen been receiving favorable news coverage?
Media stories about RGEN stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Repligen earned a media sentiment score of 0.13 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.94 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Repligen's major shareholders?
Repligen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.28%), OppenheimerFunds Inc. (4.55%), Dimensional Fund Advisors LP (2.32%), Federated Investors Inc. PA (2.13%), Stephens Investment Management Group LLC (2.13%) and Palisade Capital Management LLC NJ (1.74%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which major investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Wells Fargo & Company MN, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Sei Investments Co., Citigroup Inc., RMB Capital Management LLC and Blair William & Co. IL. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which major investors are buying Repligen stock?
RGEN stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Dimensional Fund Advisors LP, Russell Investments Group Ltd., Federated Investors Inc. PA, UBS Group AG, Pier Capital LLC, Cortina Asset Management LLC and Palisade Capital Management LLC NJ. View Insider Buying and Selling for Repligen.
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $46.29.
How big of a company is Repligen?
Repligen has a market capitalization of $1.99 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
